Metsera to Present at TD Cowen’s 45th Annual Health Care Conference
A live webcast of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. A replay of the webcast will be available for ...
Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation
Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...
Metsera started by Guggenheim at buy on obesity drug opportunity
Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...
Why this newly public biotech could become a force in obesity treatments
Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...
This weight-loss drug stock could deliver a 90% return in 2025
Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
Metsera initiated with an Outperform at Evercore ISI
Evercore ISI analyst Umer Raffat initiated coverage of Metsera (MTSR) with an Outperform rating. Metsera has a full portfolio of GLP-1 ...
https//beincrypto.com1d
MicroStrategy Makes its Largest Bitcoin Purchase of 2025 at Nearly $2 Billion
Michael Saylor buys 20,356 BTC for $1.99 billion, funding purchases with stock sales as shares drop 16%. Bitcoin's slump adds more risk.
Metsera (MTSR): Among Stocks Insiders Spent The Most Money On Recently
We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a ...
24/7 Wall St. on MSN16d
Insider Buying Surges in February, Especially in These 6 Stocks
In January, the number of notable insider purchases was somewhat muted. But with the turn of the calendar page, insider enthusiasm has returned. Warren Buffett continues to build a stake in a media ...
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
Metsera, Inc. (Nasdaq: MTSR) (“Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone (NuSH) analog peptides to treat obesity, ...